Skip to main content
Erschienen in: Allergo Journal 2/2020

25.03.2020 | Anaphylaxie | Übersicht

Venom immunotherapy in Europe and the United States

verfasst von: Beatrice Bilò, Matteo Martini, Chiara Tontini, Leonardo Antonicelli

Erschienen in: Allergo Journal | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background: Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas.
Purpose: This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019.
Literatur
1.
Zurück zum Zitat Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76CrossRef Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76CrossRef
2.
Zurück zum Zitat Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014;69:1397-404PubMedCrossRef Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014;69:1397-404PubMedCrossRef
3.
Zurück zum Zitat Golden DBK, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol 2017;118:28-54CrossRef Golden DBK, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol 2017;118:28-54CrossRef
4.
Zurück zum Zitat Sturm GJ, Varga E M, Roberts G, Mosbech H, Bilò MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy 2018;73:744-64PubMedCrossRef Sturm GJ, Varga E M, Roberts G, Mosbech H, Bilò MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy 2018;73:744-64PubMedCrossRef
5.
Zurück zum Zitat Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-8 Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-8
6.
Zurück zum Zitat Oude Elberink JNG, De Monchy JGR, Van Der Heide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82PubMedCrossRef Oude Elberink JNG, De Monchy JGR, Van Der Heide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82PubMedCrossRef
7.
Zurück zum Zitat Oude Elberink J, Van Der Heide S, Guyatt G, Dubois A. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006;118:699-704 Oude Elberink J, Van Der Heide S, Guyatt G, Dubois A. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006;118:699-704
8.
Zurück zum Zitat Bilò MB, Kamberi E, Tontini C, Marinangeli L, Cognigni M, Brianzoni MF, et al. High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: a real-life experience. J Allergy Clin Immunol Pract 2016;4:327-329.e1 Bilò MB, Kamberi E, Tontini C, Marinangeli L, Cognigni M, Brianzoni MF, et al. High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: a real-life experience. J Allergy Clin Immunol Pract 2016;4:327-329.e1
9.
Zurück zum Zitat Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006;36:704-13 Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006;36:704-13
10.
Zurück zum Zitat Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ. Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 2001;31:740-6 Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ. Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 2001;31:740-6
11.
Zurück zum Zitat Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-98PubMedCrossRef Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-98PubMedCrossRef
12.
Zurück zum Zitat Tilmant L, Dessaint JP, Tsicopoulos A, Tonnel AB, Capron A. Concomitant augmentation of CD4+ CD45R+ suppressor/inducer subset and diminution of CD4+ CDw29+ helper/inducer subset during rush hyposensitization in hymenoptera venom allergy. Clin Exp Immunol 1989;76:13-8 Tilmant L, Dessaint JP, Tsicopoulos A, Tonnel AB, Capron A. Concomitant augmentation of CD4+ CD45R+ suppressor/inducer subset and diminution of CD4+ CDw29+ helper/inducer subset during rush hyposensitization in hymenoptera venom allergy. Clin Exp Immunol 1989;76:13-8
13.
Zurück zum Zitat Fallarino F, Grohmann U. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 2011;18:2215-21PubMedCrossRef Fallarino F, Grohmann U. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 2011;18:2215-21PubMedCrossRef
14.
Zurück zum Zitat Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001;31:3704-13PubMedCrossRef Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001;31:3704-13PubMedCrossRef
15.
Zurück zum Zitat van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013;131:1204-12 van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013;131:1204-12
16.
Zurück zum Zitat Varga E M, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009;39:1353-7CrossRef Varga E M, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009;39:1353-7CrossRef
18.
Zurück zum Zitat Punnonen J, de Waal Malefyt R, van Vlasselaer P, Gauchat JF, de Vries JE. IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-9 Punnonen J, de Waal Malefyt R, van Vlasselaer P, Gauchat JF, de Vries JE. IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-9
19.
Zurück zum Zitat Eržen R, Košnik M, Šilar M, Korošec P. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012;67: 822-30PubMedCrossRef Eržen R, Košnik M, Šilar M, Korošec P. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012;67: 822-30PubMedCrossRef
20.
Zurück zum Zitat Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG. Diagnosis of hymenoptera venom allergy. Allergy 2005;60:1339-49PubMedCrossRef Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG. Diagnosis of hymenoptera venom allergy. Allergy 2005;60:1339-49PubMedCrossRef
21.
Zurück zum Zitat Bilò MB, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019;29:180-205PubMedCrossRef Bilò MB, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019;29:180-205PubMedCrossRef
22.
Zurück zum Zitat Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668-74PubMedCrossRef Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668-74PubMedCrossRef
23.
Zurück zum Zitat Bilò MB, Cichocka-Jarosz E, Pumphrey R, Oude-Elberink JN, Lange J, Jakob T, et al. Self-medication of anaphylactic reactions due to hymenoptera stings-an EAACI task force consensus statement. Allergy 2016;71:931-43PubMedCrossRef Bilò MB, Cichocka-Jarosz E, Pumphrey R, Oude-Elberink JN, Lange J, Jakob T, et al. Self-medication of anaphylactic reactions due to hymenoptera stings-an EAACI task force consensus statement. Allergy 2016;71:931-43PubMedCrossRef
24.
Zurück zum Zitat Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U, EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70PubMedCrossRef Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U, EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70PubMedCrossRef
25.
Zurück zum Zitat Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC, et al. Diagnosis and management of hymenoptera venom allergy: British society for allergy and clinical immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41:1201-20CrossRef Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC, et al. Diagnosis and management of hymenoptera venom allergy: British society for allergy and clinical immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41:1201-20CrossRef
26.
Zurück zum Zitat Golden DBK, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011;127:852-4.e1-23CrossRef Golden DBK, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011;127:852-4.e1-23CrossRef
27.
Zurück zum Zitat Golden DBK, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009;123:1371-5PubMedCrossRef Golden DBK, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009;123:1371-5PubMedCrossRef
28.
Zurück zum Zitat Bilò MB, Martini M, Pravettoni V, Bignardi D, Bonadonna P, Cortellini G, et al. Large local reactions to hymenoptera stings: outcome of re-stings in real life. Allergy 2019;74(10):1969-76. https://doi.org/10.1111/all.13863PubMedCrossRef Bilò MB, Martini M, Pravettoni V, Bignardi D, Bonadonna P, Cortellini G, et al. Large local reactions to hymenoptera stings: outcome of re-stings in real life. Allergy 2019;74(10):1969-76. https://​doi.​org/​10.​1111/​all.​13863PubMedCrossRef
29.
Zurück zum Zitat Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;70:897-909PubMedCrossRef Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;70:897-909PubMedCrossRef
30.
Zurück zum Zitat Rodríguez Del Rio P, Pitsios C, Tsoumani M, Pfaar O, Paraskevopoulos G, Gawlik R, et al. Physicians' experience and opinion on contraindications to allergen immunotherapy: the NSIT survey. Ann Allergy Asthma Immunol 2017;118:621-628.e1 Rodríguez Del Rio P, Pitsios C, Tsoumani M, Pfaar O, Paraskevopoulos G, Gawlik R, et al. Physicians' experience and opinion on contraindications to allergen immunotherapy: the NSIT survey. Ann Allergy Asthma Immunol 2017;118:621-628.e1
31.
Zurück zum Zitat Ruëff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S, et al. Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin Exp Allergy 2014;44:736-46CrossRef Ruëff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S, et al. Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin Exp Allergy 2014;44:736-46CrossRef
32.
Zurück zum Zitat Aeberhard J, Haeberli G, Müller U, Helbling A. Specific immunotherapy in hymenoptera venom allergy and concomitant malignancy: a retrospective follow-up focusing on effectiveness and safety. J Investig Allergol Clin Immunol 2017;27:370-7PubMedCrossRef Aeberhard J, Haeberli G, Müller U, Helbling A. Specific immunotherapy in hymenoptera venom allergy and concomitant malignancy: a retrospective follow-up focusing on effectiveness and safety. J Investig Allergol Clin Immunol 2017;27:370-7PubMedCrossRef
33.
Zurück zum Zitat Köhler J, Blank S, Müller S, Bantleon F, Frick M, Huss-Marp J, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol 2014;133:1383-1389.e6CrossRef Köhler J, Blank S, Müller S, Bantleon F, Frick M, Huss-Marp J, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol 2014;133:1383-1389.e6CrossRef
34.
Zurück zum Zitat Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol 2016;138:1663-1671.e9PubMedCrossRef Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol 2016;138:1663-1671.e9PubMedCrossRef
35.
Zurück zum Zitat Blank S, Etzold S, Darsow U, Schiener M, Eberlein B, Russkamp D, et al. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Hum Vaccin Immunother 2017;13:2482-9CrossRef Blank S, Etzold S, Darsow U, Schiener M, Eberlein B, Russkamp D, et al. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Hum Vaccin Immunother 2017;13:2482-9CrossRef
36.
Zurück zum Zitat Stoevesandt J, Hofmann B, Hain J, Kerstan A, Trautmann A. Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and vespula venom. Allergy Asthma Clin Immunol 2013;9:33. Stoevesandt J, Hofmann B, Hain J, Kerstan A, Trautmann A. Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and vespula venom. Allergy Asthma Clin Immunol 2013;9:33.
37.
Zurück zum Zitat Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002;109:556-62.PubMedCrossRef Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002;109:556-62.PubMedCrossRef
38.
Zurück zum Zitat Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003;361:1001-6CrossRef Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003;361:1001-6CrossRef
39.
Zurück zum Zitat Tankersley MS, Ledford DK. Stinging insect allergy: state of the art 2015. J Allergy Clin Immunol Pract 2015;3:315-22PubMedCrossRef Tankersley MS, Ledford DK. Stinging insect allergy: state of the art 2015. J Allergy Clin Immunol Pract 2015;3:315-22PubMedCrossRef
40.
Zurück zum Zitat de Groot H. Allergy to bumblebees. Curr Opin Allergy Clin Immunol 2006;6:294-7 de Groot H. Allergy to bumblebees. Curr Opin Allergy Clin Immunol 2006;6:294-7
41.
Zurück zum Zitat Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JNG. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009;64:1237-45PubMedCrossRef Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JNG. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009;64:1237-45PubMedCrossRef
42.
Zurück zum Zitat Müller UR, Ring J. When can immunotherapy for insect sting allergy be stopped? J Allergy Clin Immunol Pract 2015;3:324-8PubMedCrossRef Müller UR, Ring J. When can immunotherapy for insect sting allergy be stopped? J Allergy Clin Immunol Pract 2015;3:324-8PubMedCrossRef
43.
Zurück zum Zitat Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998;101:298-305 Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998;101:298-305
44.
Zurück zum Zitat Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12 Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12
45.
Zurück zum Zitat Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993;92:831-6PubMedCrossRef Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993;92:831-6PubMedCrossRef
46.
Zurück zum Zitat Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000;105:385-90PubMedCrossRef Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000;105:385-90PubMedCrossRef
47.
Zurück zum Zitat Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018;6:1368-72PubMedCrossRef Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018;6:1368-72PubMedCrossRef
48.
Zurück zum Zitat Tracy JM, Golden DBK. Hymenoptera venom extracts in clinical practice. J Allergy Clin Immunol Pract 2018;6:1856-62PubMedCrossRef Tracy JM, Golden DBK. Hymenoptera venom extracts in clinical practice. J Allergy Clin Immunol Pract 2018;6:1856-62PubMedCrossRef
49.
Zurück zum Zitat Bilò BM, Bonifazi F. Advances in hymenoptera venom immunotherapy. Curr Opin Allergy Clin Immunol 2007;7:567-73PubMedCrossRef Bilò BM, Bonifazi F. Advances in hymenoptera venom immunotherapy. Curr Opin Allergy Clin Immunol 2007;7:567-73PubMedCrossRef
50.
Zurück zum Zitat Pantera B, Hoffman DR, Carresi L, Cappugi G, Turillazzi S, Manao G, et al. Characterization of the major allergens purified from the venom of the paper wasp polistes gallicus. Biochim Biophys Acta 2003;1623:72-81CrossRef Pantera B, Hoffman DR, Carresi L, Cappugi G, Turillazzi S, Manao G, et al. Characterization of the major allergens purified from the venom of the paper wasp polistes gallicus. Biochim Biophys Acta 2003;1623:72-81CrossRef
51.
Zurück zum Zitat Severino MG, Campi P, Macchia D, Manfredi M, Turillazzi S, Spadolini I, et al. European polistes venom allergy. Allergy 2006;61:860-3PubMedCrossRef Severino MG, Campi P, Macchia D, Manfredi M, Turillazzi S, Spadolini I, et al. European polistes venom allergy. Allergy 2006;61:860-3PubMedCrossRef
52.
Zurück zum Zitat Stern A, Wüthrich B, Müllner G. Successful treatment of occupational allergy to bumblebee venom after failure with honeybee venom extract. Allergy 2000;55:88-91PubMedCrossRef Stern A, Wüthrich B, Müllner G. Successful treatment of occupational allergy to bumblebee venom after failure with honeybee venom extract. Allergy 2000;55:88-91PubMedCrossRef
53.
Zurück zum Zitat Potiwat R, Tanyaratsrisakul S, Maneewatchararangsri S, Manuyakorn W, Rerkpattanapipat T, Samung Y, et al. Solenopsis geminata (tropical fire ant) anaphylaxis among Thai patients: its allergens and specific IgE-reactivity. Asian Pac J Allergy Immunol 2018;36:101-8 Potiwat R, Tanyaratsrisakul S, Maneewatchararangsri S, Manuyakorn W, Rerkpattanapipat T, Samung Y, et al. Solenopsis geminata (tropical fire ant) anaphylaxis among Thai patients: its allergens and specific IgE-reactivity. Asian Pac J Allergy Immunol 2018;36:101-8
54.
Zurück zum Zitat Schiener M, Eberlein B, Moreno-Aguilar C, Pietsch G, Serrano P, McIntyre M, et al. Application of recombinant antigen 5 allergens from seven allergy-relevant hymenoptera species in diagnostics. Allergy 2017;72: 98-108PubMedCrossRef Schiener M, Eberlein B, Moreno-Aguilar C, Pietsch G, Serrano P, McIntyre M, et al. Application of recombinant antigen 5 allergens from seven allergy-relevant hymenoptera species in diagnostics. Allergy 2017;72: 98-108PubMedCrossRef
55.
Zurück zum Zitat Jakob T, Müller U, Helbling A, Spillner E. Component resolved diagnostics for hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2017;17:363-72PubMedPubMedCentralCrossRef Jakob T, Müller U, Helbling A, Spillner E. Component resolved diagnostics for hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2017;17:363-72PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Blank S, Bilò MB, Ollert M. Component-resolved diagnostics to direct in venom immunotherapy: important steps towards precision medicine. Clin Exp Allergy 2018;48:354-64CrossRef Blank S, Bilò MB, Ollert M. Component-resolved diagnostics to direct in venom immunotherapy: important steps towards precision medicine. Clin Exp Allergy 2018;48:354-64CrossRef
57.
Zurück zum Zitat Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2019;19:614-22PubMedCrossRef Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2019;19:614-22PubMedCrossRef
58.
Zurück zum Zitat Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011;66:1322-9PubMedCrossRef Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011;66:1322-9PubMedCrossRef
59.
Zurück zum Zitat Bilò MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol 2010;10:330-6PubMedCrossRef Bilò MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol 2010;10:330-6PubMedCrossRef
60.
Zurück zum Zitat Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 2004;59:589-95PubMedCrossRef Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 2004;59:589-95PubMedCrossRef
61.
Zurück zum Zitat Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol 2009;103:57-61CrossRef Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol 2009;103:57-61CrossRef
62.
Zurück zum Zitat Bilò MB, Cinti B, Brianzoni MF, Braschi MC, Bonifazi M, Antonicelli L. Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal basal serum tryptase concentrations. J Allergy 2012;2012:1-6CrossRef Bilò MB, Cinti B, Brianzoni MF, Braschi MC, Bonifazi M, Antonicelli L. Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal basal serum tryptase concentrations. J Allergy 2012;2012:1-6CrossRef
63.
Zurück zum Zitat Golden DBK, Bernstein DI, Freeman TM, Tracy JM, Lang DM, Nicklas RA. AAAAI/ACAAI joint venom extract shortage task force report. J Allergy Clin Immunol Pract 2017;5:330-2PubMedCrossRef Golden DBK, Bernstein DI, Freeman TM, Tracy JM, Lang DM, Nicklas RA. AAAAI/ACAAI joint venom extract shortage task force report. J Allergy Clin Immunol Pract 2017;5:330-2PubMedCrossRef
64.
Zurück zum Zitat Bilò MB, Martini M, Berra D, Scarpa A, Losappio L, Quercia O, et al. Hymenoptera venom immunotherapy: how to safely switch to the same venom from a different manufacturer. J Investig Allergol Clin Immunol 2018;28: 205-8PubMedCrossRef Bilò MB, Martini M, Berra D, Scarpa A, Losappio L, Quercia O, et al. Hymenoptera venom immunotherapy: how to safely switch to the same venom from a different manufacturer. J Investig Allergol Clin Immunol 2018;28: 205-8PubMedCrossRef
65.
Zurück zum Zitat Houliston L, Nolan R, Noble V, Pascoe E, Hobday J, Loh R, et al. Honeybee venom immunotherapy in children using a 50-μg maintenance dose. J Allergy Clin Immunol 2011;127:98-9PubMedCrossRef Houliston L, Nolan R, Noble V, Pascoe E, Hobday J, Loh R, et al. Honeybee venom immunotherapy in children using a 50-μg maintenance dose. J Allergy Clin Immunol 2011;127:98-9PubMedCrossRef
66.
Zurück zum Zitat Konstantinou GN, Manoussakis E, Douladiris N, Hatziioannou A, Giavi S, Saxoni-Papageorgiou P, et al. A 5 year venom immunotherapy protocol with 50 μg maintenance dose: safety and efficacy in school children. Pediatr Allergy Immunol 2011;22:393-7PubMedCrossRef Konstantinou GN, Manoussakis E, Douladiris N, Hatziioannou A, Giavi S, Saxoni-Papageorgiou P, et al. A 5 year venom immunotherapy protocol with 50 μg maintenance dose: safety and efficacy in school children. Pediatr Allergy Immunol 2011;22:393-7PubMedCrossRef
67.
Zurück zum Zitat Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027-32PubMedCrossRef Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027-32PubMedCrossRef
68.
Zurück zum Zitat Müller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005;5:343-7PubMedCrossRef Müller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005;5:343-7PubMedCrossRef
69.
Zurück zum Zitat Ruëff F, Placzek M, Przybilla B. Mastocytosis and hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006;6:284-8PubMedCrossRef Ruëff F, Placzek M, Przybilla B. Mastocytosis and hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006;6:284-8PubMedCrossRef
70.
Zurück zum Zitat Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol 2011;156:90-8 PubMedCrossRef Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol 2011;156:90-8 PubMedCrossRef
71.
Zurück zum Zitat Goldberg A, Confino-Cohen R. Bee venom immunotherapy - how early is it effective? Allergy. 2010;65:391-5PubMedCrossRef Goldberg A, Confino-Cohen R. Bee venom immunotherapy - how early is it effective? Allergy. 2010;65:391-5PubMedCrossRef
72.
Zurück zum Zitat Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80PubMedCrossRef Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80PubMedCrossRef
73.
Zurück zum Zitat Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European academy of allergology and clinical immunology. Allergy 2000;55:1005-10PubMedCrossRef Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European academy of allergology and clinical immunology. Allergy 2000;55:1005-10PubMedCrossRef
74.
Zurück zum Zitat Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-111.e5CrossRef Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-111.e5CrossRef
75.
Zurück zum Zitat Stoevesandt J, Trautmann A. Lessons from times of shortage: interchangeability of venom preparations and dosing protocols. Allergy 2019;74:1392-5PubMedCrossRef Stoevesandt J, Trautmann A. Lessons from times of shortage: interchangeability of venom preparations and dosing protocols. Allergy 2019;74:1392-5PubMedCrossRef
76.
Zurück zum Zitat Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44-8PubMedCrossRef Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44-8PubMedCrossRef
Metadaten
Titel
Venom immunotherapy in Europe and the United States
verfasst von
Beatrice Bilò
Matteo Martini
Chiara Tontini
Leonardo Antonicelli
Publikationsdatum
25.03.2020
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 2/2020
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-020-0747-y

Weitere Artikel der Ausgabe 2/2020

Allergo Journal 2/2020 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.